Australia · Delayed Price · Currency is AUD Cochlear Earnings Call Transcripts
Fiscal Year 2026
-
First half results were impacted by the Nexa launch, leading to a 2% revenue decline and 17% net profit margin, with strong second half growth expected. FX headwinds and competitive pressures affected margins and share, but restructuring and growth initiatives are underway.
Fiscal Year 2025
-
The AGM reviewed solid financial results, with sales and profit growth, increased dividends, and strong R&D investment. Board renewal, global expansion, and sustainability were emphasized, while shareholders raised questions on strategy, competition, and market risks.
-
Revenue grew 4% year-over-year with strong Cochlear implant and emerging market growth, but services declined 10% due to U.S. consumer hesitancy and a smaller eligible base. The Nexa system launch and continued R&D investment support a positive outlook, though China pricing and U.S. uncertainty remain headwinds.
-
Net sales rose 6% with strong implant and acoustics growth, but services revenue declined due to U.S. cost pressures. Guidance is maintained at the lower end, with increased cloud investment and a major new product launch expected mid-year.
Fiscal Year 2024
-
Record revenue and profit growth were achieved, with increased dividends and strong cash reserves. Board renewal and diversity advanced, major product launches and acquisitions supported strategic growth, and ESG progress continued. Shareholders' questions addressed governance, innovation, and market opportunities.
-
Revenue grew 15% to AUD 2.26 billion with strong profit and margin performance, driven by cochlear implant and Osia segment growth. FY25 guidance targets 6–11% profit growth, continued R&D investment, and capacity expansion, while services growth is expected to slow.